New drug cocktail shows promise for EGFR lung cancer
NCT ID NCT05299125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a combination of three drugs—amivantamab, lazertinib, and pemetrexed—as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. The study includes 54 participants across Latin America. Researchers want to see if this combo can keep the cancer from growing for at least 18 months. It is an early-stage study, so results are not yet conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amivantamab, lazertinib, and pemetrexed (drugs)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with EGFR-mutated lung cancer, potentially improving how long the cancer stays under control.
What could go wrong
This is a small, single-arm Phase 2 trial with no comparison group, so results are preliminary. The drugs may cause side effects like infusion reactions or lung inflammation, and the combination may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BP - A Beneficência Portuguesa de São Paulo
São Paulo, 01323-030, Brazil
-
Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, 91751-443, Brazil
-
Centro de Tratamento de Tumores Botafogo (Oncoclínicas)
Rio de Janeiro, 22250-905, Brazil
-
Hospital Erasto Gaertner
Curitiba, Paraná, 81520-060, Brazil
-
Hospital Evangélico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Espírito Santo, 29308-065, Brazil
-
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Ribeirão Preto, São Paulo, 14015-010, Brazil
-
Hospital de Amor de Barretos
Barretos, São Paulo, 14784400, Brazil
-
Hospital de Base de São José do Rio Preto
São José do Rio Preto, São Paulo, 15090-000, Brazil
-
ICESP - Instituto do Câncer do Estado de São Paulo
São Paulo, 01246-000, Brazil
-
INCA - Instituto Nacional de Câncer
Rio de Janeiro, 20230-130, Brazil
-
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90050-170, Brazil
-
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, 59062-000, Brazil
-
Pronutrir - Oncologia e Nutrição
Fortaleza, Ceará, 60810-180, Brazil
-
São Camilo Oncologia
São Paulo, 04014-002, Brazil